Advancements in Treatment Strategies for HER2+ Metastatic Breast Cancer: Insights from Experts at the Duke Cancer Center

Opinion
Video

In this Cancer Network Around the Practice program, Susan Dent, MD discusses the case of a 66-year-old patient with grade 3 triple-positive breast cancer who presents with multiple liver and bone metastases after front-line treatment with trastuzumab and letrozole.

Recent Videos
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
Related Content
97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

Chia Jie Tan;Connor Willis;Trang Au;Matthew Schabath, PhD;Chenghui Li;Kristen Kelley;Xiaoqing Xu;Leah Park;Clara Lam;Sandhya Mehta;Jackie Kwong;Diana Brixner;David Stenehjem
April 17th 2025
Article
Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer

TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer

Sara M. Tolaney, MD, MPH;Paolo D’Amico;Liyi Jia;Kim M. Hirshfield;Fatima Cardoso
April 16th 2025
Article
A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Reducing Post-Mastectomy Disparities in Breast Cancer Minority Populations

Rachel A. Greenup, MD, MPH
December 23rd 2024
Podcast

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

Charlotta Wadsten;Karuna Mittal;Pat W. Whitworth;Chirag Shah, MD;Frank Vicini, MD;Naamit Gerber;Melissa Krystel-Whittemore;Clayton C. Yates;Balasubramanyam Karanam;Walter Bell;Charles E. Cox, MS, FACS;Abigail Beard;Geza Acs;Steven C. Shivers;David J. Dabbs;Jess Savala;Mark Mentrikoski;Troy Bremer
April 14th 2025
Article
Miami Breast Cancer Conference Provided Exciting Updates and Engaging Discussions

Miami Breast Cancer Conference Provided Exciting Updates and Engaging Discussions

Neil M. Iyengar, MD
April 14th 2025
Article

Neil M. Iyengar, MD, discussed the most prevalent discussions and exciting updates from the 2025 Miami Breast Cancer Conference.